Amyotrophic Lateral Sclerosis Clinical Trials in Baltimore, Maryland

9 studies are recruiting for amyotrophic lateral sclerosis in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

   The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare …

   Stage

   Phase 3

   Ages

   18 to 80

   Site

   Johns Hopkins University, Baltimore, Maryland

   Locations

   55 in total

   Run by

   Prilenia

   See if you can join NCT07322003 on ClinicalTrials.gov

2. A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

   The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to <80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genet…

   Stage

   Phase 1

   Ages

   18 to 79

   Site

   USA003, Baltimore, Maryland

   Locations

   7 in total

   Run by

   Insmed Gene Therapy LLC

   See if you can join NCT07290062 on ClinicalTrials.gov

3. ASSESS ALL ALS Study

   The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Heal…

   Stage

   Not phased

   Ages

   18 and older

   Site

   John Hopkins University, Baltimore, Maryland

   Locations

   37 in total

   Run by

   St. Joseph's Hospital and Medical Center, Phoenix

   See if you can join NCT06578195 on ClinicalTrials.gov

4. PREVENT ALL ALS Study

   The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Heal…

   Stage

   Not phased

   Ages

   18 and older

   Site

   John Hopkins University, Baltimore, Maryland

   Locations

   32 in total

   Run by

   St. Joseph's Hospital and Medical Center, Phoenix

   See if you can join NCT06581861 on ClinicalTrials.gov

5. Investigation on the Cortical Communication (CortiCom) System

   The CortiCom system consists of 510(k)-cleared components: platinum PMT subdural cortical electrode grids, a Blackrock Microsystems patient pedestal, and an external NeuroPort Neural Signal Processor. Up to two grids will be implanted in the brain, for a total channel count of up to 128 channels, f…

   Stage

   Not phased

   Ages

   22 to 70

   Site

   Johns Hopkins Medicine, Baltimore, Maryland

   Run by

   Johns Hopkins University

   See if you can join NCT03567213 on ClinicalTrials.gov

6. Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

   This study aims to study the feasibility of psilocybin therapy for patients with Amyotropic Lateral Sclerosis (ALS) with depressed mood. The secondary objective is to assess its impact on depression, quality of life, hopelessness, and functional status in this patient population.

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland

   Run by

   Johns Hopkins University

   See if you can join NCT06656702 on ClinicalTrials.gov

7. ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

   ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Johns Hopkins University, Baltimore, Maryland

   Locations

   27 in total

   Run by

   Mayo Clinic

   See if you can join NCT04363684 on ClinicalTrials.gov

8. Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis

   Researchers will evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered Amisodin in healthy adult subjects through a randomized, double-blind, placebo-controlled Phase 1 study consisting of two parts: single ascending dose (SAD) and multiple ascending dose (MAD). The fo…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Pharmaron, Inc., Baltimore, Maryland

   Run by

   PRG Science & Technology Co., Ltd.

   See if you can join NCT07221240 on ClinicalTrials.gov

9. Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

   The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).

   Stage

   Phase 3

   Ages

   18 to 81

   Site

   Johns Hopkins Medicine Brain Science Institute, Baltimore, Maryland

   Locations

   56 in total

   Run by

   AB Science

   See if you can join NCT03127267 on ClinicalTrials.gov